On April 3, 2017, the Company completed the sale of the Commercial Business to Ipsen. The Commercial Business represented a discontinued operation since the disposal of the Commercial Business was a strategic shift that had a major effect on the Company’s operations and financial results. The Company will not have further significant involvement in the operations of the discontinued Commercial Business. The operating results of the Commercial Business are reported as discontinued operations, net of tax in the consolidated statements of operations and comprehensive loss for all periods presented.

The consolidated financial statements for the years ended December 31, 2019 and 2018 reflect the operations of the Commercial Business as a discontinued operation. Discontinued operations for the years ended December 31, 2019 and 2018 includes the following:

(in thousands)	Years Ended December 31,
	2019			2018
Expenses:
Research and development expenses		—			171
Total expenses		—			171
Other income and expenses:
Gain on sale of Commercial Business		5,000			28,000
Income from discontinued operations	$	5,000		$	27,829
Income tax expense		(1,065	)		(7,568	)
Total income from discontinued operations	$	3,935		$	20,261

During the years ended December 31, 2019 and 2018, the Company received $5.0 million and $28.0 million of the potential $33.0 million in milestone payments related to the development and commercialization of ONIVYDE, respectively. The Company included the $5.0 million and $28.0 million in discontinued operations because the amounts directly relate to the Commercial Business, which was classified as a discontinued operation. The Company also recorded $0.2 million of research and development expense in discontinued operations in the year ended December 31, 2018, as this expense is directly associated with the $28.0 million in milestones. The Company received all of the net milestone payments that related to the development and commercialization of ONIVYDE under the Servier Agreement of $33.0 million as of December 31, 2019.